

**Urgent Field Safety Notice****EliA SmD<sup>P</sup> Well, Art.No. 14-5624-01, lot numbers 0018 and 0019**  
**Field Safety Corrective Action**

---

Date: December 28, 2015


Dear Customer,

The purpose of this letter is to inform you that Phadia AB, part of Thermo Fisher Scientific, is performing a field safety corrective action, which is more fully described below.

Upon conducting complaint investigations, we found unusually high number of positive results with EliA SmD<sup>P</sup> Well lots, which are not due to anti-Sm antibodies. We are currently investigating the root cause of this issue.

**Product affected:**

All equivocal and positive patient sample results measured with the following lots are potentially incorrect and are thus considered to be invalid.

<b>Product</b>	<b>EliA SmD<sup>P</sup> Well</b>	
<b>REF</b>	<b>LOT</b>	
<b>14-5624-01</b>	<b>0018</b>	<b>2016-11-30</b>
	<b>0019</b>	<b>2017-03-31</b>

**Description of the problem:**

Analysis of patient samples received in complaint investigations showed that several of these samples caused unspecific signals up to 22 U/ml on EliA SmD<sup>P</sup> well lots 0018 and 0019. The nonspecific signals are neither caused by anti-Sm antibodies nor by anti-streptavidin antibodies (see limitation in Directions for Use), but are due to other unspecific signals with an as yet unknown cause.

All equivocal and positive results ( $\geq 7$  EliA U/ml) on EliA SmD<sup>P</sup> well lots 0018 and 0019 are potentially incorrect and must be considered invalid. All samples with a result  $\geq 7$  U/ml should be retested with an appropriate alternative assay for anti-Sm antibody detection, when possible. To our knowledge, there is no indication that negative results generated with EliA SmD<sup>P</sup> well lots 0018 and 0019 are affected.

**Actions to be taken by the customer/user:**

- 1) Identify all patient results performed with EliA SmD<sup>P</sup> Well, Art.No. 14-5624-01, lots 0018 and 0019 (Code CTL0I = lot 0018, CTL0J = lot 0019) that are  $\geq 7$  EliA U/ml and inform the physicians that these equivocal or positive results are invalid.
- 2) Retest all samples with a result  $\geq 7$  EliA U/ml with an appropriate alternate assay for anti-Sm antibody detection, if possible.
- 3) Any remaining material at the laboratory's disposal of EliA SmD<sup>P</sup> Wells lots 0018 and 0019 must only be used following the restrictions as informed of in this Field Safety Notice. It is the laboratory's responsibility to assure relevant tests are applied to confirm equivocal or positive results.
- 4) Request a refund or credit for tests affected. No return of product to the manufacturer is required.

**Transmission of this Notification:**

Please ensure that this notice is shared with anyone who needs to be made aware within your organization, or to any organization on which this notification potentially has an impact.

Phadia needs your assistance with our efforts to process this corrective action. We are requesting that a responsible member of your laboratory sign and return a copy of the attached Acknowledgement Form to verify receipt of this letter. Please complete the last page of this letter and either scan/email or FAX it to:

*TBD, commercial Organizations contact person:*

Name

Address

Telephone

E-mail

We apologize for any inconvenience this may cause.  
If you have any questions, please contact us.

Sincerely,

---

**EliA SmD<sup>P</sup> Well Field Safety Notice**

The information in this Field Safety Notice was read and understood by all relevant personnel in our laboratory. We acknowledge that this information applies to the product EliA SmD<sup>P</sup> Well (Art.No. 14-5624-01, lots 0018 and 0019) and the recommended actions described to be taken by the customer/user will be performed to the best of our ability.

I hereby acknowledge receipt of this notification:

Date: \_\_\_\_\_

Signature: \_\_\_\_\_

(Please print name): \_\_\_\_\_

Name of  
laboratory: \_\_\_\_\_

**E-mail a signed, scanned copy or fax to *(to be defined by Commercial Organizations)*:**

Name  
ImmunoDiagnostics  
Thermo Fisher Scientific

Address  
Office; Mobile; Fax

Email: xxxxxx@thermofisher.com